Incyte Genomics Inc (INCY) Dividend History

Company News

• Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight

  The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development.

  GlobeNewswire Inc.

  Featured Companies: PFE SLRX
• Why Incyte Stock Was Tanking This Week

  Incyte's investigational drug povorcitinib met its primary endpoint in two phase 3 trials for treating moderate to severe hidradenitis suppurativa, but some analysts were expecting better results given the drug's performance in phase 2 trials. The drug will face competition from UCB's Bimzelx, which is already approved by the FDA.

  The Motley Fool
• Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

  Incyte reported mixed results from its late-stage Opzelura studies in prurigo nodularis, a skin condition with itchy firm lumps. The TRuE-PN1 study met its primary endpoint, but the TRuE-PN2 study missed statistical significance due to a high placebo response.

  Benzinga
• Cathie Wood's ARK trades Incyte, Recursion stock, buys Blade Air Mobility - Investing.com Canada

  Cathie Wood's ARK ETF made several strategic trades, including selling a significant position in Incyte, buying more Recursion Pharmaceuticals, and acquiring shares of Blade Air Mobility.

  Investing.com

  Featured Companies: BLDE RXRX
• Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

  Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.

  Zacks Investment Research

  Featured Companies: ALXO